Back to Search Start Over

Donor glucose-6-phosphate dehydrogenase deficiency decreases blood quality for transfusion

Authors :
Francis, Richard O.
D'Alessandro, Angelo
Eisenberger, Andrew
Soffing, Mark
Yeh, Randy
Coronel, Esther
Sheikh, Arif
Rapido, Francesca
La Carpia, Francesca
Reisz, Julie A.
Gehrke, Sarah
Nemkov, Travis
Thomas, Tiffany
Schwartz, Joseph
Divgi, Chaitanya
Kessler, Debra
Shaz, Beth H.
Ginzburg, Yelena
Zimring, James C.
Spitalnik, Steven L.
Hod, Eldad A.
Source :
Journal of Clinical Investigation. May, 2020, Vol. 130 Issue 5, p2270, 16 p.
Publication Year :
2020

Abstract

BACKGROUND. Glucose-6-phosphate dehydrogenase (G6PD) deficiency decreases the ability of red blood cells (RBCs) to withstand oxidative stress. Refrigerated storage of RBCs induces oxidative stress. We hypothesized that G6PD-deficient donor RBCs would have inferior storage quality for transfusion as compared with G6PD-normal RBCs. METHODS. Male volunteers were screened for G6PD deficiency; 27 control and 10 G6PD-deficient volunteers each donated 1 RBC unit. After 42 days of refrigerated storage, autologous 51-chromium 24-hour posttransfusion RBC recovery (PTR) studies were performed. Metabolomics analyses of these RBC units were also performed. RESULTS. The mean 24-hour PTR for G6PD-deficient subjects was 78.5% [+ or -] 8.4% (mean [+ or -] SD), which was significantly lower than that for G6PD-normal RBCs (85.3% [+ or -] 3.2%; P = 0.0009). None of the G6PD-normal volunteers (0/27) and 3 G6PD-deficient volunteers (3/10) had PTR results below 75%, a key FDA acceptability criterion for stored donor RBCs. As expected, fresh G6PD-deficient RBCs demonstrated defects in the oxidative phase of the pentose phosphate pathway. During refrigerated storage, G6PD-deficient RBCs demonstrated increased glycolysis, impaired glutathione homeostasis, and increased purine oxidation, as compared with G6PD-normal RBCs. In addition, there were significant correlations between PTR and specific metabolites in these pathways. CONCLUSION. Based on current FDA criteria, RBCs from G6PD-deficient donors would not meet the requirements for storage quality. Metabolomics assessment identified markers of PTR and G6PD deficiency (e.g., pyruvate/lactate ratios), along with potential compensatory pathways that could be leveraged to ameliorate the metabolic needs of G6PD-deficient RBCs. TRIAL REGISTRATION. ClinicalTrials.gov NCT04081272. FUNDING. The Harold Amos Medical Faculty Development Program, Robert Wood Johnson Foundation grant 71590, the National Blood Foundation, NIH grant UL1 TR000040, the Webb-Waring Early Career Award 2017 by the Boettcher Foundation, and National Heart, Lung, and Blood Institute grants R01HL14644 and R01HL148151.<br />Introduction Red blood cell (RBC) transfusion is one of the most common therapeutic interventions for hospitalized patients (1). In particular, chronic transfusions are essential for patients with sickle cell disease [...]

Details

Language :
English
ISSN :
00219738
Volume :
130
Issue :
5
Database :
Gale General OneFile
Journal :
Journal of Clinical Investigation
Publication Type :
Academic Journal
Accession number :
edsgcl.624327933
Full Text :
https://doi.org/10.1172/JCI133530